Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedaB
a16z Bio+Health
Activity from announced rounds
Activity in this selectionlong-z-investments-3cb12046
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $330M 1 disclosed · full round size, not this investor’s share